Mycobacterium abscessus strain variability in preclinical drug development: does it really matter?

Jurriaan E M De SteenwinkelHenriëtte M MeliefsteNicole C AmmermanJurriaan E M de SteenwinkelHannelore I Bax

Published in: The Journal of antimicrobial chemotherapy (2024)

Time- and concentration-dependent drug activity against the ATCC 19977 strain seems indicative for in vitro drug behaviour against M. abscessus complex clinical isolates. Including one clinical smooth morphotype isolate alongside ATCC 19977 seems appropriate for reliable interpretation of this particular in vitro drug activity assay as part of the M. abscessus preclinical drug development pipeline.

Keyphrases

adverse drug
cell therapy
high throughput
drug induced
emergency department
mesenchymal stem cells